Great forgotten neurodegenerative diseases, Parkinson’s disease receives no National Plan unlike Alzheimer’s disease in particular. This results in a lack of coordination in the management and research, to the detriment of patients and their families.
One year after the White Paper on Parkinson’s disease , which offered twenty measures to improve the management of patients at the time of diagnosis, help them cope with their disease and boost research, progress is stalled almost. The Association France Parkinson calls the government.
Parkinson, the great “forgotten” neurodegenerative diseases
On the eve of the World Parkinson’s Day, April 11, the Association Parkinson calls on the State to launch urgently a national Parkinson Plan, like those that exist for other diseases, particularly for the Alzheimer disease . If the association has decided to act, it is estimated that Parkinson’s disease , which in France each year 14,000 new victims, is “the most overlooked of neurodegenerative diseases . ” “Today, solutions and concrete paths exist in support, but lack of resources, they are not coordinated nationally. There is no coverage of the French territory known visible and dynamic,” laments the association. Continue reading “A Parkinson when a Plan?”
At the beginning of the disease, the diagnosis of Parkinson’s disease is difficult because the symptoms can go unnoticed. Nevertheless, several criteria can now wear a reliable diagnosis … if not early.
The symptoms of Parkinson’s disease is progressive and nonspecific: fatigue, pain, rheumatism, depression … This is why the National Agency for Accreditation and Evaluation in Health (predecessor of the High Authority for Health) listed specifically in 2000 the criteria for Parkinson’s diagnosis could and should be established.
The clinical criteria for Parkinson’s disease
The diagnosis of Parkinson’s disease based on a review and examination of the patient, for symptoms previously observed. Continue reading “Parkinson’s disease: a difficult diagnosis”
Now reserved for advanced Parkinson’s disease forms, neurostimulation demonstrates real benefits at earlier stages of the disease. These results argue in favor of a wider use of this technique. Medical evidence but an economic and organizational puzzle …
Progressive, degenerative neurological disease, Parkinson’s disease is characterized by symptoms such as motor slowness, difficulty in movement, tremors, an uncertain balance and rigidity. It results from the degeneration of nerve cells that produces dopamine, an essential for the control of movements and body coordination neurotransmitter. In France, 150,000 people are affected by the disease, and there are 6 000 to 9 000 new cases per year. The incidence increases with age.
The standard treatment based on medicines antiparkinsonian taken orally (levodopa, dopamine agonists …) that will increase the amount of dopamine in the brain and stimulate the brain regions in which dopamine has an effect. To-onset of the disease, patients see their symptoms disappear, the term ” honeymoon . ” But this period did not last after 4-6 years, an interim period is characterized by the resurgence of the motor and / or dyskinesia (abnormal movements) that reflects a fluctuation of the beneficial effect of treatment conditions. It was during this period that other treatments can be considered as deep brain stimulation . It is estimated that 400 to 500 patients a year benefit. Continue reading “Parkinson: towards expanded indications of neurostimulation”